A Prostacyclin Analogue-Incorporated Nanoparticles Attenuates Ischemia Reperfusion Injury In Rat Heart

Introduction: We developed a liposome-based biocompatible nanoparticle for drug-delivery-system for myocardial ischemia reperfusion (I/R) injury, in which the nanoparticle was selectively accumulated in the ischemic area. YS-1301 is a synthetic prostacyclin IP receptor agonist, acting as a vasodilatory, proangiogenic and anti-inflammatory cytokine-inducer. Hypothesis: YS-1301 incorporated liposome-based nanoparticle (YS1301-NP) may attenuate I/R myocardial injury. Methods: Myocardial I/R injury was induced by 30 minutes’ occlusion of the left coronary artery in adult male Sprague-Dawley rats. At 5 minutes prior to the reperfusion, PBS, NP alone, YS-1301 (3 mg/kg) alone or YS-1301NP (3 mg/kg) were intravenously injected (n=10 each) respectively. Results: As a result of 24 hours after myocardial I/R, the concentration of YS-1301 after the injection of YS-1301NP was approximately 10-fold higher in ischemic area compared when in administrating YS-1301 alone. Infarct size in the area at risk of infarction was ...